LTS and Grand River Aseptic Manufacturing to Form Strategic Alliance for Sterile Fill-Finish of Sorrel™ Wearable Injector Containers.
This article delves into the benefits and challenges of prefilled and preloaded drug delivery systems and highlights Sorrel™’s pioneering efforts in this field.
We are pleased to announce that we have been awarded as a Best Managed Company 2024.
LTS today announced the successful commercial validation of a semi-automated production line for the Sorrel™ wearable drug delivery platform.
We are dedicated to pioneering medical devices that set the [...]
Coherus and LTS have been working in partnership to receive approval for the delivery of Udenyca® OBI.
LTS announced today that it will support Micron Biomedical, Inc. as selected CDMO partner in the manufacturing scale-up of Micron´s Microarray Patch technology.
After more than 45 years at LTS, of which 8 as Board Member, Michael Hoffmann will retire from LTS on 31 December 2023. The position of Chief Operating Officer will be taken over by Dr. Claudia Schaefer as of 01.01.2024.
The agreement is for a proprietary (S)-ketamine formulation, administered sub-lingually via an oral thin film (OTF) and Awakn will have global exclusivity of its use for Treatment of Addiction, Anxiety Disorders, and Eating Disorders.
Grant for the support the development of MAP for self-administration of contraceptives for women in low- and middle-income countries (LMICs)
